About Basking Biosciences
Basking Biosciences is a company based in Columbus (United States) founded in 2019. Basking Biosciences has raised $89.8 million across 5 funding rounds from investors including The Ohio State University, HHS and RTW Investments. The company has 3 employees. Basking Biosciences operates in a competitive market with competitors including Acticor Biotech, Remedy Pharmaceuticals, Alveron Pharma, Remedium Bio and 4TEEN4 Pharmaceuticals, among others.
- Headquarter Columbus, United States
- Employees 3
- SectorsHealthcare
- Email••••••••
- Phone•••• ••••
- Website baskingbiosciences.com
- Social LinkedIn
- Legal Name Basking Biosciences, Inc
- Total Equity Funding$89.8M (USD)
in 5 rounds
- Latest Funding Round$55M (USD), Series C
Feb 2024
- InvestorsThe Ohio State University
& 10 more
- Employee Count3
Funding Insights of Basking Biosciences
Basking Biosciences has successfully raised a total of $89.8M across 5 strategic funding rounds. The most recent funding activity was a Series C round of $55 million completed in February 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $89.8M
- Total Rounds 5
- Last Round Series C — $55M
- First Round $575,179
(Jun 2020)
- Investors Count 11
All 5 funding rounds of Basking Biosciences with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Feb 2024 | $55M | Series C | – | Arch Venture Partners | |
| Oct 2023 | $27.5M | Series A | – | – | – |
| Dec 2020 | $5.4M | Seed | – | Rev1 Ventures, Broadview Ventures | – |
| Sep 2020 | $1.9M | Seed | – | – | – |
| Jun 2020 | $575,179 | Grant | – | – |
11 investors in total: 11 institutional.
Investors in Basking Biosciences
Basking Biosciences has secured backing from 11 investors, including venture fund and institutional investors. Prominent investors backing the company include The Ohio State University, HHS and RTW Investments.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Venture capital firm focused on life science companies | 1986 | archventure.com | Chicago, United States | |
Investment firm scaling software and technology companies from early to late stages. | – | insightpartners.com | - | |
- | – | solasbio.com | - | |
Life Sciences focused VC firm investing in the US | 2010 | rtwfunds.com | New York, United States | |
Startup Studio building companies in the US & Europe and Angel Network for Ohio based companies | – | rev1ventures.com | Columbus, United States | |
- | – | longviewventures.tcc.mode | - | |
Seed-stage life sciences investments are made in the US. | – | broadviewventures.org | Boston, United States | |
Biotechnology startups are incubated and funded by Viva BioInnovator. | 2014 | vivabioinnovator.com | Shanghai, China | |
- | – | platanusventures.com | - | |
Multiple courses and degrees are offered across diversified academic streams. | 1870 | osu.edu | United States |
Investor details for Basking Biosciences
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Basking Biosciences
13 people are tracked at Basking Biosciences (6 in leadership, 7 in board & advisors); the tracked headcount is 3.
| Name | Role | Group |
|---|---|---|
Rich Shea | CEO | Leadership |
Richard Shea | President And Chief Operating Officer | Leadership |
Stacy Nelson | Head, Program Manager | Leadership |
Julia C. Owens | Chief Executive Officer | Leadership |
Shahid Nimjee | Founder & Chief Medical Officer | Leadership |
Rob Hughes | CFO | Leadership |
Jun Mao | Board Member | Board & advisors |
Michael Hill | Clinical Trial Advisor | Board & advisors |
Bruce Sullenger | Founder & Scientific Advisor | Board & advisors |
Thomas Needham | Board Member | Board & advisors |
Ryan Helon | Board Member | Board & advisors |
Dan Meyers | Board Member | Board & advisors |
Sabah Oney | Board Member | Board & advisors |
Complete people profiles for Basking Biosciences
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Basking Biosciences
3 dated milestones of Basking Biosciences across 5 years, from founding to its latest funding, stage changes and deals.
- Founded Basking Biosciences is founded.
- Funding First funding round of $575K.
- Funding Latest funding round, Series C, of $55.0M.
Competitors of Basking Biosciences
Basking Biosciences operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Acticor Biotech, Remedy Pharmaceuticals, Alveron Pharma, Remedium Bio and 4TEEN4 Pharmaceuticals, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| acticor-biotech.com | 2013 | Paris, France | $31.36M | – | Immunotherapeutics are developed for ischemic stroke treatment using monoclonal antibodies. | |
| remedypharmaceuticals.com | 2004 | New York, United States | $22.76M | 6 | Intravenous formulation for acute central nervous system conditions such as stroke (ischemic and hemorrhagic), traumatic brain injury. | |
| alveron.com | 2019 | Nijmegen, Netherlands | $11.79M | – | Drugs for haemorrhagic stroke and intracranial haemorrhage are developed. | |
| remedium-bio.com | 2020 | Needham, United States | $3.5M | – | Gene therapies for immune and age-related conditions are developed. | |
| 4teen4.de | 2013 | Hennigsdorf, Germany | $30.68M | – | Therapeutics and diagnostics for cardiovascular diseases are developed. | |
| zzbiotech.com | 2006 | Houston, United States | – | – | Genetically engineered proteins for stroke and brain disorders are developed. | |
| aurumbiosciences.com | 2015 | Glasgow, United Kingdom | $6.3M | 6 | Novel oxygen carriers and MRI software for stroke are developed. | |
| aptatargets.com | 2014 | Madrid, Spain | $2.98M | – | Provider of therapeutic solutions for ischemic diseases | |
| infensabioscience.com | 2021 | Sydney, Australia | $15.6M | – | Peptide drugs for cardiovascular disorders are developed. |
Detailed competitors of Basking Biosciences
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Basking Biosciences
The website of Basking Biosciences (baskingbiosciences.com) receives about 1.5K visits a month.
- Monthly visits1.5K
▼ 19% vs previous month
Latest news on Basking Biosciences
Complete news archive for Basking Biosciences
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Similar companies to Basking Biosciences
10 companies that operate in the same segment as Basking Biosciences (Neurology), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Novel biopharmaceutical medicines are developed for unmet medical needs. | 2003 | Dublin, Ireland | USD 265 M | USD 4.27 B | 2,800 | |
Immuno-modulatory therapies for dementia and neurodegenerative disorders are developed. | 2013 | San Francisco, California, United States | USD 214.78 M | USD 21.05 M | 211 | |
Developer of therapeutics for psychiatric and neurologic diseases | 2002 | New York, New York, United States | USD 80.87 M | USD 250.31 M | 600 | |
Biologics platform developed for intracellular delivery in rare diseases. | 2016 | Boston, Massachusetts, United States | USD 175.25 M | USD 25.42 M | 183 | |
Developer of therapies for the treatment of musculoskeletal disorders | 2007 | Woburn, Massachusetts, United States | USD 62 M | USD 85.55 M | 692 | |
MR-interfaced ultrasound devices for cancer and neurology treatments are provided. | 1999 | Tirat Carmel, Haifa District, Israel | USD 574.2 M | – | – | |
AI-driven drug discovery platform for neurological diseases based on patients biomarkers | 2019 | San Francisco, California, United States | USD 144.72 M | – | 76 | |
Small molecule drugs for rare diseases are developed. | 1998 | South Plainfield, New Jersey, United States | USD 248.1 M | USD 1.73 B | 939 | |
Developer of small molecule therapeutics for endocrine and CNS disorders | 1992 | San Diego, California, United States | USD 10 M | USD 2.86 B | 1,800 | |
Developer of antibodies to treat complement-mediated neurodegenerative diseases | 2011 | San Francisco, California, United States | USD 256 M | – | 100 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Basking Biosciences
Basking Biosciences was founded in 2019 and raised its 1st funding round 1 year after it was founded.
Basking Biosciences is headquartered in Columbus, United States. It is registered at Columbus, Ohio, United States.
Rich Shea is the current CEO of Basking Biosciences.
Basking Biosciences is a funded company, having raised a total of $89.8M across 5 funding rounds to date. The company's 1st funding round was a Grant of $575.18K, raised on Jun 2020.
Basking Biosciences has 3 employees.
Basking Biosciences was founded in 2019 in Columbus, United States, as a biotechnology firm focused on therapeutics for ischemic stroke. Drug candidate BB-031, an RNA aptamer that inhibits von Willebrand Factor, has been shown to enable vessel recanalization. Additionally, BB-025, a sequence-specific reversal oligonucleotide, is provided to neutralize the effects of BB-031. Operations center on advancing these candidates through development stages.
Basking Biosciences's top competitors include Acticor Biotech, 4TEEN4 Pharmaceuticals and Remedy Pharmaceuticals.
Basking Biosciences has 11 investors. Key investors include The Ohio State University, HHS, RTW Investments, Arch Venture Partners, and Viva BioInnovator.
Basking Biosciences operates through Basking Biosciences, Inc.